ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

New Staging System Proposed for HPV-Related Oropharyngeal Cancer

August 18, 2016

  • Tweet
  • Email
Print-Friendly Version

Currently, all oropharyngeal cancers (OPC), whether HPV-positive or HPV-negative, use the 7th edition Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) TNM staging system. Patients with HPV-positive cancers have higher overall survival than their HPV-negative counterparts by a wide margin, however. This disparity in overall survival affects outcomes research and interferes with clinical decision making because prognosis is not reflected by the current system.
Researchers of a report published earlier this year propose a new staging system for human papillomavirus (HPV)-related OPC (Lancet. 2016;17:440-451). The authors developed the system based on findings from the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) study.
The researchers explored alternative staging criteria based on current TNM staging, which is based on the tumor (T category), whether or not the cancer has reached nearby lymph nodes (N category), and metastasis (M category).
The investigators showed that applying the current TNM staging criteria to patients with HPV-positive cancers did not take into account the uniqueness of this particular cancer. They did not find differences in survival between stage groups, and the distribution of patients was unbalanced; the current criteria classified the majority of patients as having stage IV disease. Thus, they sought to develop a revised staging system that would separate patients with HPV-related OPC.
“Staging is a critical component of designing treatment plans and for predicting and helping patients understand their prognosis,” said Erich M. Sturgis, MD, professor in the department of head and neck surgery at The University of Texas MD Anderson Cancer Center in Houston and co-author of the study. “Patients with HPV-positive OPC tend to present with more advanced disease, but also typically have better survival rates than those with HPV-unrelated OPC. These cancers are markedly different and require different staging criteria.”

You Might Also Like

No related posts.

Explore This Issue
August 2016

The Study
The ICON-S study, an international effort to develop a pretreatment TNM clinical staging classification specific to HPV-positive OPC, studied 1,907 patients from seven institutions in Europe and North America, including one training center (n = 661) and six validation centers (n = 1,246). Investigators included patients with newly diagnosed non-metastatic OPC undergoing either primary surgery or primary radiotherapy with or without chemotherapy and determined HPV status with p16 staining or in situ hybridization.
Among all patients, according to the UICC/AJCC staging system, the five-year overall survival rate was similar among those with TNM stage I (88%), II (82%), III (84%), and IVA disease (81%) but significantly lower in those with stage IVB disease (60%). For N stage, five-year overall survival was similar for N0 (80%), N1–N2a (87%), and N2b (83%) but was significantly lower for N3 disease (59%). No difference in five-year survival was found between T4a and T4b disease (58% versus 57%).

Pages: 1 2 | Single Page

Filed Under: Features, Head and Neck, Practice Focus Tagged With: cancer, HPV, oropharyngeal cancer, stagingIssue: August 2016

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Complications for When Physicians Change a Maiden Name
    • Vertigo in the Elderly: What Does It Mean?
    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?
    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • What Happens to Medical Students Who Don’t Match?
    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?
    • Vertigo in the Elderly: What Does It Mean?
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Novel Bioabsorbable Plate Associated with Lower Leak Risk in Patients Receiving Endoscopic Skull Base Repair
    • New Findings Support Use of Cemiplimab as Neoadjuvant Therapy in Patients with Resectable Cutaneous Squamous Cell Carcinoma
    • Kinetic Oscillation Stimulation an Effective, Lasting Second-Line Treatment for Patients with Nonallergic Rhinitis
    • Otolaryngologists Vary Significantly in Choice of Injectable Materials for Vocal Fold Injection Augmentation
    • COVID-19 Infection May Be Associated with Unique Manifestation of Facial Nerve Paralysis/Palsy

Polls

Do you believe that having more otolaryngologists appear on mainstream media outlets is a good thing for the field?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2023 The Triological Society. All Rights Reserved.
ISSN 1559-4939